Evolus (NASDAQ:EOLS) is a specialty pharmaceutical company focused on the development and commercialization of products within the medical aesthetics market. The company’s flagship product, Jeuveau (prabotulinumtoxinA-xvfs), is an FDA-approved neuromodulator indicated for temporary improvement in the appearance of moderate to severe glabellar lines. Evolus leverages a precision-targeted approach to aesthetic medicine, collaborating closely with aesthetic practitioners to support product education, training, and patient safety.
Jeuveau, often referred to as “NewTox,” is manufactured through a partnership with Daewoong Pharmaceutical and marketed by Evolus in the United States and Canada. Since receiving FDA clearance in early 2019, the company has built a dedicated commercial infrastructure to reach dermatologists, plastic surgeons, and other aesthetic providers. Evolus supports its customers through a combination of clinical data, hands-on training workshops, and digital resources designed to enhance patient outcomes and practitioner confidence.
Founded in 2018 and headquartered in Newport Beach, California, Evolus launched its initial public offering on the NASDAQ under the ticker EOLS in December 2018. The company is led by President and Chief Executive Officer David Moatazedi, who brings extensive experience in specialty pharmaceuticals and commercial operations. Under his leadership, Evolus has expanded its reach and strengthened its brand presence amid a competitive aesthetic landscape.
In addition to its North American footprint, Evolus is pursuing opportunities to extend Jeuveau’s approval and distribution into select international markets. The company continues to invest in clinical research aimed at broadening the application of its neuromodulator platform into new treatment areas. Evolus’s business strategy combines targeted product innovation with strategic partnerships to position itself for long-term growth in medical aesthetics.
